Next generation sequencing (NGS) refers to a DNA sequencing technology that has revolutionized genomic research. The potential capabilities of NGS allow the entire human genome sequence in a single day. Genome sequencing was traditionally performed using Sanger’s sequencing method, which is comparatively slower and a tedious process. However, NGS has superseded the former in terms of cost-efficiency, run-time, and wider clinical applications. Some of the popular services offered under the arena of NGS include targeted sequencing that is vital and highly informative in case of drug development and diagnostic applications.
NGS has recently become popular in the diagnosis of immunological disorders, infectious diseases, non-invasive prenatal diagnostics, hereditary disorders and helps in therapeutic decision making. The Next-generation Sequencing Services Market is expected to grow at a CAGR of 20.4% from 2021 to 2028 to reach $14.1 billion by 2028.
Here are the top 10 companies in NGS Services Market
Illumina, Inc. (U.S.)
Illumina, Inc.is a provider of sequencing- and array-based solutions for genomic and genetic analysis. Earlier, the company operated its business through two segments: Core Illumina and Helix. In April 2019, the company deconsolidated the Helix business segment, resulting in the single reportable segment, known as Core Illumina. The Core Illumina business segment is further categorized into Products and Service and Other Revenue. The Services and Other Revenue segment of the company offer whole-genome sequencing, noninvasive prenatal testing (NIPT), product support, and genotyping services. The Services and Other Revenue segment is divided into two sub-segments: Sequencing and Microarray. The NGS services are being offered through the Sequencing sub-segment.
The company serves government laboratories, genomic research centers, academics institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has its manufacturing sites and laboratories located in the U.S., the U.K., and Singapore. The services of the company are mainly performed by Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited laboratories. The company, through its distributors, distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East, and Africa. The major NGS service providers of the company are ACGT, Inc. (U.S.) AMES S.r.l. (Italy), ACT Genomics Co., LTD. (China), and Fasteris (Switzerland), among others. Illumina Australia Pty. Ltd. (Australia), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan) are some subsidiaries of the company offering NGS Services.
QIAGEN N.V. (Netherlands)
Qiagen N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academia and pharmaceutical research. The company offers its products through only one reportable segment and provides its products in two major markets: Molecular Diagnostics and Life Sciences. The company’s product offerings include diagnostics solutions, PCR products, genomic or NGS products, consumables and instruments for sample technologies, and others. The company offers more than 500 core products consisting of instruments, kits, and bioinformatics, in addition to a wide range of NGS services like RNA Sequencing Services, DNA Sequencing Service, Whole Genome Amplification Service, and RNA Isolation Service, among others. These NGS services are offered under the genomic or NGS products group.
The company markets products in more than 130 countries across the globe. The company has its facilities located in countries like the U.S., China, Germany, Poland, Philippines, Denmark, Romania, Spain, the U.K., and others. The sales of the company operate through distributors and sales subsidiaries. The company also sells its products directly to the customers. In the Americas, Europe, Asia, and Australia, the sales function mainly through the subsidiaries. As of December 2020, company had employed over 902 personnel for R&D. The major subsidiaries of the company include Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen Hamburg GmbH (Germany), and more.
PerkinElmer, Inc. (U.S.)
PerkinElmer, Inc. is a multinational company that offers its products and solutions & services for the life sciences, diagnostics, and applied markets. PerkinElmer, Inc. operates its business through two reporting segments: Discovery & Analytical Solutions and Diagnostics. The Diagnostics segment of the company offers NGS services; apart from that, the segment also offers reagents, instruments, assay platforms, and software required for diagnosis. The company provides NGS Services through its subsidiary PerkinElmer Genomics (U.S.)
Through its advanced technologies and various solutions, the company helps to solve the issues in growing areas of reproductive health, emerging market diagnostics, and applied genomics. PerkinElmer Genetics offers a broad range of genetic testing solutions that helps to provide insight into the complex nature of inherited and rare diseases.
The company has its manufacturing and R&D facilities located in the U.S., China, Japan, and Germany, among others. The company has a strong network of sales and marketing channels; as of January 2021, the company employed around 5,500 sales and service personnel in over 38 countries and for marketing its products and services in over 190 countries. The company sells products and services predominantly through distributors. Some of the subsidiaries of the company offering NGS Services are PerkinElmer (India) Pvt Ltd. (India) and PerkinElmer Sverige AB (Sweden), among others.
Eurofins Scientific SE (Luxembourg)
Eurofins Scientific S.E. is a life science company that offers a range of analytical testing services across different industries. The customer offers its products and services in five key areas: Clinical Diagnostics, Environment Testing, Food, and Feed Testing, Consumer Product Testing, and Bio-Pharmaceutical Services. The company provides NGS Services within its Bio-pharmaceutical Services offerings. The Biopharmaceutical Services of the company are provided to the chemical, pharmaceutical, biotechnology, medical device, and cosmetic industries.
The company has its geographic presence in over 60 countries in Europe, North and South America, Asia-Pacific, and the Middle East and Africa. The company offers NGS services through its subsidiaries Diatherix (U.S.), Eurofins Viracor, Inc (U.S), and Eurofins BioPharma Product Testing Australia Pty Ltd. (Australia.), among others
Meticulous Research in its latest publication on Global Next-generation Sequencing Services Market has predicted the growth of 20.4% during the forecast year 2021–2028
Macrogen, Inc. (South Korea)
Macrogen, Inc. is a biotechnology company offering products in the area of Precision Medicine, Next Generation Sequencing (NGS), Clinical Diagnostics, Microarray, Oligo, Gene synthesis, Personal Genome, and Capillary Electrophoresis Sequencing (CES), among others. The company provides next generation sequencing services such as the whole genome, de novo, exome, targeted, transcriptomics, metagenome, single cell multi-omics sequencing, and epigenome sequencing. In addition to this, the company also provides services such as whole genome resequencing, standard sequencing, primer walking, fragment analysis, Oligo synthesis, cloning, human identification, SNP/mutation analysis, Sanger sequencing, and 16S/18S/26S rRNA and ITS region sequencing services.
The company in February 2000 became the first bio venture in Korea to be listed on the Korean Securities Dealers Automated Quotations (KOSDAQ). The company provides its services to over 18,000 researchers across 153 countries globally. As of 2021, the company performed over 30 million cases of genome sequencing. The company is actively involved in the R&D of genomic and genetic analyses. Macrogen, Inc. provides genome research services in Korea and across the globe. The company has its subsidiaries and branches located in U.S., Europe, Singapore, Japan, and Spain. Macrogen Japan Corp. (Japan), Psomagen, Inc. (U.S.), and Macrogen Asia Pacific Pte Ltd. (Singapore) are some subsidiaries of the company offering NGS Services.
LGC Limited is one of the global players in the life sciences industry, serving clinical diagnostics, research, government, pharmaceutical, food, and other applied markets. The company provides quality assurance solutions, genomic analysis tools, and drug development solutions. LGC Limited, operating as a subsidiary of KKR & Co. L.P. LGC Limited, was formerly known as LGC Teddington Limited and changed its name to LGC Limited in March 2002. The genomic analysis tools business offers NGS Services; apart from that, it also offers research grade and (Good Manufacturing Practice) GMP oligonucleotides, molecular biology reagents, next generation sequencing reagents and kits, oligo synthesis reagents and instruments, PCR reagents and instruments, and sample preparation reagents and instruments. The NGS services of the company are offered through the company’s subsidiary, LGC Biosearch Technologies (U.S.).
The company also provides various other services including, consultancy, consumer product testing, DNA/RNA extraction, drug, and alcohol testing, drug development, paternity and proficiency testing, reference measurements, sport, and specialized analytical services, government services, and others. The company’s laboratories and offices are located in Canada, China, Germany, the U.S., the U.K., Ireland, and India. The subsidiary LGC Biosearch Technologies has an indirect presence in approximately 60 countries through its distributors. Company in April 2020, introduced a new NGS laboratory for agricultural biotechnology services.
GENEWIZ, Inc. (U.S.)
Founded in 1999 and headquartered in New Jersey, U.S., GENEWIZ, Inc. is one of the leading providers of R&D genomics services. The company offers services for next generation sequencing, Sanger sequencing, plasmid DNA preparation, PCR, gene synthesis, oligo synthesis, pre-clinical and clinical synthesis, and other services for pharma and biotech companies. The company offers its services in the research areas of cancer, infectious disease, biomarkers, agriculture, metagenomics, and antibody discovery, among others. GENEWIZ, Inc. offers both standard and custom solutions for the NGS library preparation, sequencing, extraction, and bioinformatics. The company provides its products majorly to academic institutions and to pharma and biotech companies. GENEWIZ, Inc. is a subsidiary company of Brooks Automation, Inc. (U.S). GENEWIZ, Inc. also provides raw sequence data with adjuvant quality scores, certificate of analysis, and signed QAU statement.
GENEWIZ, Inc. has its geographic presence in the U.S., China, Germany, Japan, and the U.K. In January 2021, the National Cancer Institute (NCI) selected the company as the Genome Characterization Center to provide whole exome sequencing for research projects of NCI at its Center for Cancer Genomics for over three years. Moreover, in October 2018, the company expanded its CLIA-compliant service offering into next generation sequencing (NGS). The new CLIA-compliant NGS services included whole genome sequencing and whole exome sequencing services.
Beijing Genomics Institute (China)
Established in 1999 and headquartered in Shenzhen, China, Beijing Genomics Institute (BGI) is a provider of proteomics and genomics sequencing services. The company provides a wide range of integrated genomic sequencing and proteomic solutions and services for pharmaceutical companies, medical institutions, health care providers, and other organizations. The company provides its services to over 100 countries globally. As of 2021, the company had a headcount of 6,000 employees. The majority of the sequencing services of the company are done on the DNBSEQ NGS platform. The company, in December 2019, offered free services of whole genome resequencing to support the researchers in the management of fall armyworm spodopterafrugiperda species so as to protect the agriculture market globally. The company has its offices located in Denmark, the U.S., China, and Japan.
On July 14, 2017, BGI Genomics announced its initial public offering (IPO) of 40.1 million shares at a list price of USD 2.0 (RMB 13.64) per share. In 2017, BGI Group announced its ownership from private to public.
SciGenom Labs Pvt. Ltd (India)
Founded in 2010 and headquartered in Kerala, India. Scigenom Labs Pvt. Ltd is a biotechnology company offering products and services in the area of genomics. The company’s product offerings include primary and secondary antibodies. The company’s service offerings are molecular DNA cloning, NGS, protein expression, custom monoclonal antibody, and assay development. Scigenom Labs Pvt. Ltd provides NGS services and genomic sequencing to its clients in India and internationally.
The offices of the company are located in the state of Tamil Nadu and Telangana in India, and in California in the U.S.; SciGenom Labs Pvt. Ltd provides its genomic research services through its subsidiary AgriGenome Labs (AgGenome). AgGenome started in 2013 and provides genome sequencing, editing, and various NGS services for Plant, Animal & Microbes. The services are mainly offered to academic and government institutions. AgGenome genomics platforms include PacBio Sequel, Illumina sequencers, and ABI 3730xl Sanger, among others.
Founded in 2013 and headquartered in California, U.S., MedGenome Inc. is a core provider of precision medicine. It provides unique genomic solutions in diabetes, immune-oncology, cardiology, ophthalmology, and other rare diseases. The company offers NGS Services, BioFXBioinformatics Services, and Immuno Oncology Solutions, in addition to a wide range of fast, high quality, and cost-efficient next generation sequencing (NGS) services to advance clients’ genomic analysis needs. The company’s state-of-the-art facility is equipped with the latest Illumina NGS platforms, including MiSeq, HiSeq 2500, NovaSeq, and HiSeq X.
MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. The company also has a strong presence in the Indian sub-continent, and the offices of the company are located in the U.S., India, and Singapore.
Popular Mentions: Genotypic Technology Pvt. Ltd. DNA Link, Inc., Otogenetics Corporation, Novogene Co., Ltd., CD Genomics, Foundation Medicine, Inc., and SeqLL, Inc.
Authoritative Research on the NGS Services Market 2021-2028
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
- Impact of COVID-19 Pandemic on the NGS Services Market
Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=5041